Skip to content
Open access

Real-world outcomes for multiple myeloma patients after apheresis for planned chimeric antigen receptor T-cell therapy

Sep 2026 · World Journal of Experimental Medicine · Vol 16 · 0 citations · 15 references
Medicine

TL;DR

The outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy are described, to characterise the apheresis-to-infusion interval and the reasons for, and correlates of, failure to reach infusion, and to report progression-free survival (PFS) and overall survival (OS) anchored at the date of apheresis.

Abstract

Background

Chimeric antigen receptor T-cell (CAR-T) therapy is highly active in relapsed/refractory multiple myeloma (RRMM), but manufacturing creates an obligatory waiting period between apheresis and infusion. Patients may deteriorate, progress or die during this window. Analyses that begin follow-up at infusion exclude these patients entirely and cannot describe the experience of all patients who enter the CAR-T pathway.

Aim

To describe, in an intention-to-collect fashion, the outcomes of all RRMM patients who underwent T-cell apheresis for planned CAR-T therapy; to characterise the apheresis-to-infusion interval and the reasons for, and correlates of, failure to reach infusion; and to report progression-free survival (PFS) and overall survival (OS) anchored at the date of apheresis. The study was descriptive; it was not designed to estimate the causal effect of CAR-T infusion on survival.

Methods

Retrospective single-centre cohort of all RRMM patients undergoing T-cell apheresis for CAR-T at Hackensack University Medical Center between 1 January 2021 and 30 April 2024. PFS and OS were calculated from apheresis by the Kaplan-Meier method with Greenwood 95% confidence intervals (CIs) and numbers at risk. Groups were compared with the log-rank test; baseline characteristics with the Wilcoxon rank-sum and Fisher exact tests. Because infusion is a post-baseline, time-dependent event, the association between infusion and survival was additionally examined using a Mantel-Byar time-dependent Cox model and a 60-day landmark analysis. Correlates of non-infusion were examined by univariable logistic regression; multivariable modelling was not performed owing to the small number of events.

Results

Of 99 patients undergoing apheresis, 87 (87.9%, 95%CI: 79.8-93.6) were infused and 12 (12.1%, 95%CI: 6.4-20.2) were not. Median follow-up was 14.0 months [interquartile range (IQR): 8.2-20.7]. Median apheresis-to-infusion interval was 54 days (IQR 46-62; range 37-202; n = 84 evaluable). Contrary to our preliminary report, baseline disease phenotype differed significantly between groups: Extramedullary disease was present in 9/12 (75.0%) non-infused vs 17/87 (19.5%) infused patients (P < 0.001), and plasma cell leukaemia in 3/12 (25.0%) vs 3/87 (3.4%) (P = 0.017). Age, prior lines of therapy (median 5 in both), high-risk cytogenetics (36.4% vs 34.1%) and Revised International Staging System distribution did not differ. The commonest reasons for non-infusion were progressive disease or myeloma-related death (7/12, 58.3%), non-myeloma death (2/12, 16.7%), manufacturing or collection failure (2/12, 16.7%) and infection (1/12, 8.3%). The median time from apheresis to the attrition event was 44 days (IQR 30-72). Median PFS from apheresis was 17.5 months (95%CI: 12.7-21.6) in infused patients vs 1.5 months (95%CI: 0.8-2.3) in non-infused patients; median OS was not reached vs 1.9 months (95%CI: 1.0-6.2) (both log-rank P < 0.001). In the time-dependent Cox model the hazard ratio for death associated with infusion was 0.24 (95%CI: 0.11-0.53), substantially closer to the null than the unadjusted comparison, illustrating how much of the apparent difference reflects the time-dependent nature of the exposure and confounding by disease phenotype.

Conclusion

In this descriptive cohort, roughly one in eight patients who underwent apheresis never received CAR-T, and attrition clustered before the median time to infusion and among patients with extramedullary disease or plasma cell leukaemia. These data support shortening manufacturing turnaround, prioritising patients with aggressive phenotypes for expedited slots and intensified bridging, and reporting outcomes from apheresis using analytic methods that respect the time-dependent nature of infusion.

Read PDF

Similar papers

Open access Oct 2026

Venetoclax as Salvage Treatment for Relapsed/Refractory B-ALL Post-CAR-T Therapy.

BACKGROUND Despite high early response rates following chimeric antigen receptor T-cell therapy (CAR-T) for relapsed/refractory pediatric B-cell acute lymphoblastic leukemia (B-ALL), many patients relapse, and downregulation of the antigen targeted by the CAR-T has emerged as a major challenge. Furthermore, minimal res...

Elizabeth E. Dong, Deborah E. Schiff, J. Rossoff et al. · 0 citations
Review Open access Oct 2026

T-cell-redirecting therapies in early relapsed multiple myeloma: a systematic review and network meta-analysis

Chimeric antigen receptor T cells and bispecific antibodies, are moving from late-line salvage into early relapsed multiple myeloma. Indirect comparisons in heavily pretreated patients have favored cell therapy, but whether that hierarchy holds in early relapse is unknown. We analyzed randomized phase 3 trials comparin...

Maximilian Merz, J. Souto, P. Voorhees et al. · 0 citations
Review Open access Sep 2026

CAR-T Cell Therapy: Engineering Remission in Refractory Myeloma

The determinants of response and relapse, as well as the mechanisms of antigen-positive and antigen-negative escape that next-generation approaches aim to overcome are discussed, all with the goal of extending durable remissions to every patient.

A. Sperling · 0 citations
Open access Oct 2026

Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.

Data on long-term outcomes of in vivo chimeric antigen receptor T cell (CAR‑T) therapy remain scarce. We previously reported preliminary safety and efficacy data of in vivo B-cell maturation antigen (BCMA) CAR‑T (ESO-T01), in four patients with relapsed/refractory multiple myeloma, without leukapheresis and lymphodeple...

Jia Xu, Lin Liu, Wei Xie et al. · 0 citations
Open access Oct 2026

Anti-BCMA CAR-T cell therapy for refractory / relapsed multiple myeloma: clinical experience of a center

Objective.  To evaluate the clinical efficacy of anti-BCMA CAR-T cells in patients with refractory / recurrent multiple myeloma (RRMM.) Materials and methods.   Six patients with multiple myeloma MM who had undergone significant pretreatment got anti-BCMA (B-Cell Maturation Antigen) CAR-T (Chimeric An...

Zh. M. Kozich, N. N. Klimkovich, J. Pugacheva et al. · 0 citations
Review Nov 2026

Real-world evidence supporting sustainable CAR-T-cell therapy-from access to long-term follow-up.

This review summarizes major RWE for CAR-T therapies and discusses how RWE can support operational optimization from access through long-term follow-up, and frames the integrated evaluation of basic biology, clinical data, and care processes as "Cytotherapy Operational Science," to discuss its relevance to sustainable...

Tomoyasu Jo · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.